| 2013, Soto et al. |
MA intralesional (30), Cryotherapy (20),Placebo cream (30) |
80 |
parasitological diagnosis (smears or biopsy, culture), ≥12 years of age, one ulcerative lesion ≤30 mm2 resulting in a total lesion area of ≤900 mm2
|
previous anti-leishmanial therapy (< 3 months), mucosal lesions, concomitant diseases |
6 |
42/80 (52.5%) |
L. braziliensis (36); L. guyanensis (2); L. amazonensis (2); L. lainsoni (2) |
100% reepithelialization within 6 months after the end of therapy |
3/80 (3.7%) |
| 2004, Soto et al. |
Miltefosine (89); Placebo (44) |
133 |
parasitological diagnosis (smears, culture, biopsy, monoclonal antibody), ≥12 years of age |
previous anti-leishmanial therapy (< 4 weeks), mucosal lesions, concomitant diseases, pregnancy, lactation |
6 |
53/133 (39.8%) |
L braziliensis (29); L mexicana (17); L panamensis (7) |
100% reepithelialization within 6 months after the end of therapy |
8/133 (6%) |
| 2002, Soto et al. |
New drug test # (33), Placebo (12) |
45 |
parasitological diagnosis (smears, culture, biopsy, monoclonal antibody), total ulcer lesion size < 2000 mm2, lymphadenopathy < 1 cm |
severe disease; papular or nodular lesions; mucosal lesions, concomitant diseases |
6 |
5/45 (11.1%) |
L. panamensis (5) |
100% reepithelialization by the 6-month follow-up |
8/45 (17.8%) |
| 2001, Arana et al. |
Paromomycin + MBCL (38), Placebo (38) |
76 |
parasitological diagnosis (smears, culture), age between 10–60 years (smears, culture) |
> 4 lesions; lesion > 5 cm in diameter; previousanti-leishmanial therapy; mucosal lesions, concomitant diseases |
12 |
not available |
not available |
100% reepithelialization by the 13-week follow-up |
8/76 (10.5%) |
| 1997, Neva et al. |
Topical paromomycin+ urea (23); Placebo (30) |
53 |
parasitological diagnosis (culture) |
NA |
5 |
53/53 (100%) |
L. mexicana (18), L. chagasi (35) |
100% reepithelialization within 11 weeks after the end of therapy |
6/53 (11.3%) |
| 1997, Velez et al. |
Allopurinol (60), Placebo (56); MA (66) |
182 |
parasitological diagnosis (smears, culture), age between 6–60 years; body weight appropriate for height |
Previous anti-leishmanial therapy, lesions close to the eyes; mucosal lesions, concomitant diseases, pregnancy |
12 |
not available |
not available |
100% reepithelialization within 3 months after the end of therapy with no relapse by the 12-month follow-up |
25/182 (13.7%) |
| 1995, Martha et al. |
Allopurinol+probenecid (30); SS (30); No therapy (15) |
75 |
parasitological diagnosis (smears, culture, biopsy, monoclonal antibody) |
mucosal lesions, concomitant diseases |
12 |
26/75 (34.7%) |
L. panamensis (12); L. guyanensis (7); L. braziliensis (4);L. mexicana (1); L. amazonensis (2) |
100% reepithelialization by the 70-day follow-up |
13/75 (17.3%) |
| 1993, Soto et al. |
MA (23); Pentamidine (27), Itraconazole(20); No treatment (22) |
92 |
parasitological diagnosis (smears, culture, biopsy, monoclonal antibody), age between 18–60 years |
mucosal lesions, concomitant diseases, previous anti-leishmanial therapy |
12 |
not available |
not available |
100% reepithelialization within 1.5 months after the end of therapy |
6/92 (6.5%) |
| 1992, Martinez et al. |
MA (33); Allopurinol+MA (35); Allopurinol (25), No treatment (17) |
110 |
parasitological diagnosis (smears, culture, biopsy); lesions confined to the upper portion of the trunk or arms |
allergy to antimony or allopurinol; pregnant or nursing, concomitant diseases, more than 20% above or below ideal weight |
12 |
110/110 (100%) |
L. panamensis (110) |
100% reepithelialization and negative culture within 3 months after the end of therapy |
not available |
| 1992, Navin et al. |
SS (40); Ketoconazole (38), Placebo (40) |
120 |
parasitological diagnosis (smears, culture), male gender |
mucosal lesions, concomitant diseases, previous anti-leishmanial therapy |
13 |
97/120 (80.8%) |
L. mexicana (32); L. braziliensis (63); both L. mexicana and L. braziliensis (2) |
100% reepithelialization by the 13-week follow-up |
7/120 (5.8%). |
| 1991, Guderian et al. |
SS (30); Allopurinol+probenecid (30); No treatment (15) |
75 |
parasitological diagnosis (smears, culture, biopsy, monoclonal antibody) |
mucosal lesions, concomitant diseases, less than 6 months of follow-up |
1.5 * |
23/75 (30.7%) |
L. panamensis(12); L. guyanensis (5); L. braziliensis(3); L. mexicana(3) |
>80% reepithelialization by the 1-month follow-up |
14/75 (18.7%). |
| 1990, Navin et al. |
MA (22); Localized Heat (22); Placebo (22) |
66 |
parasitological diagnosis (smears, culture), lesions<25 cm2
|
lesions in ear, near the eye, on the finger; presence of unilateral lymphadenopathy; mucosal lesions, concomitant diseases, previous anti-leishmanial therapy |
12 |
53/66 (80.3%) |
L. mexicana (13); L. braziliensis (40) |
100% reepithelialization by the 13-week follow-up |
3/66 (4.54%) |
| 1990, Saenz et al. |
Ketoconazole (22); SS (19); Placebo (11) |
52 |
parasitological diagnosis (smears, culture) |
facial or mucosal lesions; concomitant disease |
3 |
38/52 (73.1%) |
L. guyanensis (37); L. mexicana (1) |
100% reepithelialization by the 1-month follow-up |
NA |
